The pharmaceutical corporation and the 'good work' of managing women's bodies

Social Science and Medicine

Volumn 72, Issue 8, 2011, Pages 1342-1350

  Padamsee, Tasleem Juana ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Gender; Health care; Infertility; Medicalization; Menopause; Pharmaceutical corporations; Reproduction; Women

Indexed keywords

DRUG; GENDER ISSUE; HEALTH CARE; INFERTILITY; REPRODUCTION; WOMENS HEALTH; WOMENS STATUS;

ARTICLE; CLINICAL RESEARCH; CONTRACEPTION; DRUG INDUSTRY; FEMALE; FEMALE FERTILITY; HEALTH CARE; HUMAN; INFERTILITY THERAPY; INTERPERSONAL COMMUNICATION; MEDICAL PRACTICE; MENOPAUSE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; QUALITY OF LIFE; WOMEN'S HEALTH;

DRUG INDUSTRY; FEMALE; GYNECOLOGY; HUMANS; MARKETING; OBSTETRICS; PERIODICALS AS TOPIC; PERSUASIVE COMMUNICATION; REPRODUCTIVE MEDICINE; WOMEN'S HEALTH;

EID: 79954789626     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2010.10.034     Document Type: Article

References (71)

1. Altman L. Experts see bias in drug data. The New York Times 1997, C1-C8.
2. Arney J., Rafalovich A. Incomplete syllogisms as techniques of medicalization: the case of direct-to-consumer advertising in popular magazines, 1997 to 2003. Qualitative Health Research 2007, 17(1):49-60.
3. Ballard K.D., Elston M.A., Gabe J. Private and public ageing in the UK: the transition through menopause. Current Sociology 2009, 57(2):269-290.
4. Ballard K.D., Huk D.J., Wadsworth M.E.J. The role of the menopause in women's experiences of the 'change of life'. Sociology of Health & Illness 2001, 23(4):397-424.
5. Becker G., Nachtigall R.D. Eager for medicalisation: the social production of infertility as a disease. Sociology of Health & Illness 1992, 14(4):456-471.
6. Bekelman J., Li Y., Gross C. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. Journal of the American Medical Association 2003, 289:454-465.
7. Bell S. Changing ideas: the medicalization of menopause. Social Science & Medicine 1987, 26(6):535-542.
8. Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. The New England Journal of Medicine 2000, 342(20):1539-1544.
9. Conrad P. The shifting engines of medicalization. Journal of Health and Social Behavior 2005, 46(1):3-14.
10. Conrad P. The medicalization of society: On the transformation of human conditions into treatable disorders 2007, The Johns Hopkins University Press, Baltimore.
11. Conrad P., Schneider J.W. Deviance and medicalization: From badness to sickness 1980, C.V. Mosby, St. Louis.
12. Corbin J., Strauss A. Grounded theory research: procedures, canons, and evaluative criteria. Qualitative Sociology 1990, 13(1):3-21.
13. Coupland J., Williams A. Conflicting discourses, shifting ideologies: pharmaceutical, 'alternative', and feminist emancipatory texts on the menopause. Discourse & Society 2002, 13(4):419-445.
14. DeAngelis C. Conflict of interest and the public trust. Journal of the American Medical Association 2000, 284(17):2237-2238.
15. Derry P. Hormones, menopause, and heart disease: making sense of the Women's Health Initiative. Women's Health Issues 2004, 14(6):212-219.
16. Derry P. Update on hormones, menopause, and heart disease: evaluating professional responses to the Women's Health Initiative. Healthcare for Women International 2008, 29(7):720-737.
17. Dillaway H. Menopause is the "good old" women's thoughts about reproductive aging. Gender & Society 2005, 19(3):398-417.
18. Fishman J.R., Mamo L. What's in a disorder: a cultural analysis of medical and pharmaceutical constructions of male and female sexual dysfunction. Women & Therapy 2001, 24(1/2):179-193.
19. Foster P. Women and the health care industry: An unhealthy relationship? 1995, Open University Press, Buckinghamshire.
20. Freidson E. Profession of medicine: A study of the sociology of applied knowledge 1970, Dodd, Mead, New York.
21. Friedman L.S., Richter E.D. Relationship between conflict of interest and research results. Journal of General Internal Medicine 2004, 19:51-56.
22. Glaser B.G. Theoretical sensitivity: Advances in the Methodology of Grounded Theory 1978, Sociology Press, Mill Valley.
23. Greene J. Attention to "Details" etiquette and the pharmaceutical Salesmen in postwar USA. Social Studies of Science 2004, 34(2):271-292.
24. Greil J., Slauson-Blevins K., McQuillan J. The experience of infertility: a review of recent literature. Sociology of Health & Illness 2010, 32(1):140-162.
25. Gullette M.M. Menopause as magic marker: discursive consolidation/strategies for cultural combat. Discourse 1994, 17(1):93-122.
26. Haraway D. Simians, cyborgs, and women: The reinvention of nature 1991, Routledge, New York.
27. Harding J. Bodies at risk: sex, surveillance and hormone replacement therapy. Foucault, health and medicine 1997, 134-150. Routledge, New York. A. Petersen, R. Bunton (Eds.).
28. Hartley H. "Big Pharma" in our bedrooms: an analysis of the medicalization of women's sexual problems. Advances in Gender Research 2003, 7:89-129.
29. Healy D. Shaping the intimate: influences on the experience of everyday nerves. Social Studies of Science 2004, 34(2):219-245.
30. Hutcheon L., Hutcheon M. Medical "mythologies" a semiotic approach to pharmaceutical advertising. Queen's Quarterly 1987, 94(4):904-916.
31. Jenkins G.L., Inhorn M.C. Reproduction gone awry: medical anthropological perspectives. Social Science & Medicine 2003, 56:1831-1836.
32. Jutel A. Framing disease: the example of female hypoactive sexual desire disorder. Social Science & Medicine 2010, 70:1084-1090.
33. Klein R., Dumble L.J. Disempowering midlife women: the science and politics of hormone replacement therapy (HRT). Women's Studies International Forum 1994, 17(4):327-343.
34. Lakoff A. The anxieties of globalization: antidepressant sales and economic crisis in Argentina. Social Studies of Science 2004, 34(2):247-269.
35. Lane C. Shyness: How normal behavior became a sickness 2007, Yale University Press, New Haven.
36. Lawton B., Rose S., McLeod D., Dowell A. Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. British Medical Journal 2003, 327(7419):845-846.
37. Lewis J. Feminism, the menopause, and hormone replacement therapy. Feminist Review 1993, 43:38-56.
38. Lexchin J. Drug makers and drug regulators: too close for comfort. A study of the Canadian situation. Social Science & Medicine 1990, 31(11):1257-1263.
39. Lexchin J., O'Donovan O. Prohibiting or 'managing' conflict of interest? A review of policies and procedures in three European drug regulation agencies. Social Science & Medicine 2010, 70:643-647.
40. Mansfield P.K., Voda A. Woman-centered information on menopause for health care providers: findings from the midlife women's health survey. Healthcare for Women International 1997, 18(1):55-72.
41. Marco C.A., Moskop J.C., Solomon R.C., Geiderman J.M., Larkin G.L. Gifts to physicians from the pharmaceutical industry: an ethical analysis. Annals of Emergency Medicine 2006, 48(5):513-521.
42. McCrea F.B. The politics of menopause: the "discovery" of a deficiency disease. Social Problems 1983, 31(1):111-123.
43. Metzl J.M. Prozac on the couch: Prescribing gender in the era of wonder drugs 2005, Duke University Press, Durham.
44. Morgen S. Into our own hands: The women's health movement in the United States, 1969-1990 2001, Rutgers University Press, New Brunswick.
45. Moynihan R. The marketing of a disease: female sexual dysfunction. British Medical Journal 2005, 330:192-194.
46. Moynihan R., Cassels A. Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients 2005, Nation Books, New York.
47. Moynihan R., Heath I., Henry D. Selling sickness: the pharmaceutical industry and disease mongering. British Medical Journal 2002, 324(7342):886-891.
48. Organon Organon corporate website 1999, Retrieved from. http://www.organon.com.
49. Organon Organon corporate website 2008, Retrieved from. http://www.organon.com.
50. Payer L. Disease-Mongers: How doctors, drug companies, and insurers are making you feel sick 1992, John Wiley & Sons, Inc., New York.
51. Relman A. Separating continuing medical education from pharmaceutical marketing. Journal of the American Medical Association 2001, 285(15):2009-2011.
52. Rennie D., Bero L.A. Throw it away, Sam: the controlled circulation journals. American Journal of Roentgenology 1990, 13:31-35.
53. Schonberg M.A., Davis R.B., Wee C.C. After the women's health initiative: decision making and trust of women taking hormone therapy. Women's Health Issues 2005, 15:187-195.
54. Scritchfield S.A. The social construction of infertility: from private matter to social concern. Images of issues: Typifying contemporary social problems 1995, 61-97. Aldine de Gruyter, Hawthorne. 2nd ed. J. Best (Ed.).
55. Silverman M., Lee P.R. Pills, profits, and Politics 1974, University of California Press, Berkeley.
56. Sismondo S. Pharmaceutical maneuvers. Social Studies of Science 2004, 34(2):149-159.
57. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Social Science & Medicine 2008, 66:1909-1914.
58. Sismondo S. Ghosts in the machine: publication planning in the medical sciences. Social Studies of Science 2009, 39(2):171-198.
59. Smith M.C., Visconti J.A. Appeals used in prescription drug advertising. Hospital Pharmacy 1968, 3(2):5-13.
60. Starr P. The social transformation of American medicine 1982, Basic Books, New York.
61. Swanson J.M. Analyzing data for categories and description. From practice to grounded theory: Qualitative research in nursing 1986, Addison-Wesley, Menlo Park. W.C. Chenitz, J.M. Swanson (Eds.).
62. Tiefer L. Sexology and the pharmaceutical industry: the threat of co-optation. The Journal of Sex Research 2000, 37(3):273-283.
63. Tiefer L. Sex is not a natural act, and other essays 2004, Westview Press, Boulder. 2nd ed.
64. Tiefer L. Female sexual dysfunction: a case study of disease mongering and activist resistance. Public Library of Science Medicine 2006, 11 April.
65. Vertinsky P. "Run, Jane, Run" central tensions in the current debate about enhancing women's health through exercise. Women & Health 1998, 27(4):81-109.
66. Voda A., Ashton C. Fallout from the Women's Health Study: a short-lived vindication for feminists and the resurrection of hormone therapies. Sex Roles 2006, 54(5-6):401-411.
67. Washburn J. Undue influence: how the drug industry's power goes unchecked and why the problem is likely to get worse. American Prospect 2001, 13:16-22. August, b.
68. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift. Journal of the American Medical Association 2000, 283:373-380.
69. Wilson R.A. Feminine forever 1968, M. Evans and Company, New York.
70. Worcester N., Whatley M.H. The selling of HRT: playing on the fear factor. Feminist Review 1992, 41:1-26.
71. Zola I.K. Medicine as an institution of social control. Sociological Review 1972, 20(4):487-504.